Private Equity

Photo

The Evolution of Chemical Industry M&A

Every year, the chemical industry sees hundreds of mergers and acquisitions (M&A). Traditional M&A drivers, such as consolidation and portfolio extension, are still important. But many transactions also show that the nature of M&A is evolving, as chemical companies look for ways to contend with ongoing volatility and move to a more sustainable future.

Photo

Private Equity Buyers Seen as Circling Sandoz

US private equity firms Blackstone and Carlyle may make a joint offer for the Novartis generics unit Sandoz, Bloomberg reports. With six other possible bidders seen as circling Basel-based Sandoz, the news agency’s sources said this sale could shape up to be one of the biggest-ever buyout deals, valued at around $25 billion.

Photo

Lanxess and DSM to Merge Plastics under Private Equity?

Lanxess and private equity investor Advent International are reportedly discussing a transaction that could see the German company’s engineering plastics portfolios merge with the polymer-related activities being flogged off by DSM in the Netherlands. The resulting new entity would likely be controlled by Advent.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.